Literature DB >> 22954188

A novel paramagnetic substrate for detecting myeloperoxidase activity in vivo.

Mohammed S Shazeeb1, Yang Xie, Suresh Gupta, Alexei A Bogdanov.   

Abstract

Bis-phenylamides and bis-hydroxyindolamides of diethylenetriaminepentaacetic acid-gadolinium (DTPA(Gd)) are paramagnetic reducing substrates of peroxidases that enable molecular imaging of peroxidase activity in vivo. Specifically, gadolinium chelates of bis-5-hydroxytryptamide-DTPA (bis-5HT-DTPA(Gd)) have been used to image localized inflammation in animal models by detecting neutrophil-derived myeloperoxidase (MPO) activity at the inflammation site. However, in other preclinical disease models, bis-5HT-DTPA(Gd) presents technical challenges due to its limited solubility in vivo. Here we report a novel MPO-sensing probe obtained by replacing the reducing substrate serotonin (5-HT) with 5-hydroxytryptophan (HTrp). Characterization of the resulting probe (bis-HTrp-DTPA(Gd)) in vitro using nuclear magnetic resonance spectroscopy and enzyme kinetic analysis showed that bis-HTrp-DTPA(Gd) (1) improves solubility in water; (2) acts as a substrate for both horseradish peroxidase and MPO enzymes; (3) induces cross-linking of proteins in the presence of MPO; (4) produces oxidation products, which bind to plasma proteins; and (5) unlike bis-5HT-DTPA(Gd), does not follow first-order reaction kinetics. In vivo magnetic resonance imaging (MRI) in mice demonstrated that bis-HTrp-DTPA(Gd) was retained for up to 5 days in MPO-containing sites and cleared faster than bis-5HT-DTPA(Gd) from MPO-negative sites. Bis-HTrp-DTPA(Gd) should offer improvements for MRI of MPO-mediated inflammation in vivo, especially in high-field MRI, which requires a higher dose of contrast agent.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22954188      PMCID: PMC3544410     

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  24 in total

1.  Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets.

Authors:  Alexei Bogdanov; Lars Matuszewski; Christoph Bremer; Alexander Petrovsky; Ralph Weissleder
Journal:  Mol Imaging       Date:  2002 Jan-Mar       Impact factor: 4.488

2.  Serotonin protects NK cells against oxidatively induced functional inhibition and apoptosis.

Authors:  A Betten ; C Dahlgren; S Hermodsson; K Hellstrand
Journal:  J Leukoc Biol       Date:  2001-07       Impact factor: 4.962

3.  Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma.

Authors:  Mohammed S Shazeeb; Christopher H Sotak; Michael DeLeo; Alexei Bogdanov
Journal:  Cancer Res       Date:  2011-01-18       Impact factor: 12.701

4.  The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates.

Authors:  Peter Caravan; Normand J Cloutier; Matthew T Greenfield; Sarah A McDermid; Stephen U Dunham; Jeff W M Bulte; John C Amedio; Richard J Looby; Ronald M Supkowski; William DeW Horrocks; Thomas J McMurry; Randall B Lauffer
Journal:  J Am Chem Soc       Date:  2002-03-27       Impact factor: 15.419

5.  Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes.

Authors:  S Sugiyama; Y Okada; G K Sukhova; R Virmani; J W Heinecke; P Libby
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

6.  DTPA-bisamide-based MR sensor agents for peroxidase imaging.

Authors:  Manuel Querol; John W Chen; Ralph Weissleder; Alexei Bogdanov
Journal:  Org Lett       Date:  2005-04-28       Impact factor: 6.005

Review 7.  Myeloperoxidase: friend and foe.

Authors:  Seymour J Klebanoff
Journal:  J Leukoc Biol       Date:  2005-02-02       Impact factor: 4.962

8.  Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis.

Authors:  John W Chen; Wellington Pham; Ralph Weissleder; Alexei Bogdanov
Journal:  Magn Reson Med       Date:  2004-11       Impact factor: 4.668

9.  Prognostic value of myeloperoxidase in patients with chest pain.

Authors:  Marie-Luise Brennan; Marc S Penn; Frederick Van Lente; Vijay Nambi; Mehdi H Shishehbor; Ronnier J Aviles; Marlene Goormastic; Michael L Pepoy; Ellen S McErlean; Eric J Topol; Steven E Nissen; Stanley L Hazen
Journal:  N Engl J Med       Date:  2003-10-23       Impact factor: 91.245

Review 10.  Unraveling the catalytic mechanism of lactoperoxidase and myeloperoxidase.

Authors:  Elena Ghibaudi; Enzo Laurenti
Journal:  Eur J Biochem       Date:  2003-11
View more
  4 in total

1.  Peroxidase Sensitive Amplifiable Probe for Molecular Magnetic Resonance Imaging of Pulmonary Inflammation.

Authors:  Aurora Rodríguez-Rodríguez; Sergey Shuvaev; Nicholas Rotile; Chloe M Jones; Clemens K Probst; Diego Dos Santos Ferreira; Katherine Graham-O Regan; Eszter Boros; Rachel S Knipe; Jason W Griffith; Andrew M Tager; Alexei Bogdanov; Peter Caravan
Journal:  ACS Sens       Date:  2019-08-22       Impact factor: 7.711

Review 2.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

3.  Pilot study to assess visualization and therapy of inflammatory mechanisms after vessel reopening in a mouse stroke model.

Authors:  Ebba Beller; Laura Reuter; Anne Kluge; Christine Preibisch; Ute Lindauer; Alexei Bogdanov; Friederike Lämmer; Claire Delbridge; Kaspar Matiasek; Benedikt J Schwaiger; Tobias Boeckh-Behrens; Claus Zimmer; Alexandra S Gersing
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

4.  High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease.

Authors:  Youssef Z Wadghiri; Dung Minh Hoang; Anita Leporati; Matthew J Gounis; Aurora Rodríguez-Rodríguez; Mary L Mazzanti; John P Weaver; Ajay K Wakhloo; Peter Caravan; Alexei A Bogdanov
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.